When it comes to assessing risk of developing cardiovascular disease, your doctors fundamentally sort out what known risk ...

This helps in reducing calorie intake, which, when combined with lifestyle changes like diet and exercise, can lead to ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

People who take Novo Nordisk's semaglutide-based injectables Ozempic and Wegovy seem to be way less likely to die from ...

A study highlights that GLP-1 RAs are linked to a reduced risk of cirrhosis in patients with MASLD and diabetes. Learn more ...

Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical (VANI – Research Report) and keeping the price target at ...

For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, ...

WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Discover the potential of GLP-1 medications like Ozempic and Mounjaro in treating a wide range of conditions, from diabetes to addiction.